{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:55:11Z","timestamp":1793876111035,"version":"4.7.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2026.109317","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:39:39Z","timestamp":1770741579000},"page":"109317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-4094","authenticated-orcid":false,"given":"Laura","family":"Alder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trey C.","family":"Mullikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Lascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-7161","authenticated-orcid":false,"given":"Paul W.","family":"Sperduto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109317_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-56046-w","article-title":"Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases","volume":"14","author":"Kahraman","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109317_b0010","first-page":"14","article-title":"Brain metastasis in patients with small cell lung Cancer","volume":"21","author":"Li","year":"2021","journal-title":"Internat. J. General Med."},{"key":"10.1016\/j.lungcan.2026.109317_b0015","article-title":"Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials: time series analyses for 2012-2022","author":"Xiao","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0020","doi-asserted-by":"crossref","unstructured":"Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. European J Cancer 45(2) (2009), doi: 10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109317_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0030","doi-asserted-by":"crossref","unstructured":"Goldberg S, Gettinger S, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncol. 17(7) (2016), doi: 10.1016\/S1470-2045(16)30053-5.","DOI":"10.1016\/S1470-2045(16)30053-5"},{"issue":"15","key":"10.1016\/j.lungcan.2026.109317_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy Response Assessment in Neuro-Oncology (iRANO): a Report of the RANO Working Group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0040","doi-asserted-by":"crossref","unstructured":"Steindl A, Brunner TJ, Heimbach K, et al. Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years - PubMed. European journal of cancer (Oxford, England : 1990) 2022 Feb;162. DOI: 10.1016\/j.ejca.2021.12.005.","DOI":"10.1016\/j.ejca.2021.12.005"},{"issue":"33","key":"10.1016\/j.lungcan.2026.109317_b0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research brain metastases working group - PubMed","volume":"35","author":"Lin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0050","doi-asserted-by":"crossref","unstructured":"Camidge D, Lee E, Lin N, et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group - PubMed. The Lancet Oncol. 19(1) (2018), doi: 10.1016\/S1470-2045(17)30693-9.","DOI":"10.1016\/S1470-2045(17)30693-9"},{"key":"10.1016\/j.lungcan.2026.109317_b0055","unstructured":"US Food and Drug Administration: Cancer clinical trial eligibility criteria: Brain metastases\u2014Guidance for industry."},{"key":"10.1016\/j.lungcan.2026.109317_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2025.11.016","article-title":"Expanding lung cancer clinical trial criteria: a systematic review on inclusion of patients with brain metastases and leptomeningeal disease","author":"Riano","year":"2026","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109317_b0065","author":"Sperduto","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"32","key":"10.1016\/j.lungcan.2026.109317_b0070","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0075","doi-asserted-by":"crossref","unstructured":"P.W. Sperduto, K.E. Marqueen, E. Chang, et al. Improved survival and prognostication in melanoma patients with brain metastases: an update of the melanoma graded prognostic assessment \u2013 PubMed, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 43(16) (2025), doi: 10.1200\/JCO-24-01351.","DOI":"10.1200\/JCO-24-01351"},{"key":"10.1016\/j.lungcan.2026.109317_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110405","article-title":"External validation of the lung-molGPA to predict survival in patients treated with stereotactic radiotherapy for brain metastases of non-small cell lung cancer","author":"Crouzen","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0085","doi-asserted-by":"crossref","unstructured":"C. Schr\u00f6der, P. Windisch, J. L\u00fctscher, D.R. Zwahlen, R. F\u00f6rster, Frontiers | Validation and discussion of clinical practicability of the graded prognostic assessment for NSCLC adenocarcinoma patients with brain metastases in a routine clinical cohort, Front. Oncol. (2022) 13, doi: 10.3389\/fonc.2023.1042548.","DOI":"10.3389\/fonc.2023.1042548"},{"key":"10.1016\/j.lungcan.2026.109317_b0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor\u2013mutated advanced non\u2013small-cell lung cancer","author":"J\u00e4nne","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0095","doi-asserted-by":"crossref","unstructured":"B.C. Cho, E. Felip, A.I. Spira, et al. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. Ann. Oncol. (2023) 34, doi: 10.1016\/j.annonc.2023.10.062.","DOI":"10.1016\/j.annonc.2023.10.062"},{"key":"10.1016\/j.lungcan.2026.109317_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced alk-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III crown study","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109317_b0105","doi-asserted-by":"crossref","unstructured":"A. Drilon, D.R. Camidge, J.J. Lin, et al. Repotrectinib in, N. Engl. J. Med. 390(2) (2024)118\u2013131. (In eng), doi: 10.1056\/NEJMoa2302299.","DOI":"10.1056\/NEJMoa2302299"},{"key":"10.1016\/j.lungcan.2026.109317_b0110","doi-asserted-by":"crossref","unstructured":"M. P\u00e9rol, W. Li, N.A. Pennell et al., Taletrectinib in ROS1+ non\u2013small cell lung cancer: TRUST, J. Clin. Oncol. 43(16) (2025), doi:10.1200\/JCO-25-00275.","DOI":"10.1200\/JCO-25-00275"},{"key":"10.1016\/j.lungcan.2026.109317_b0115","doi-asserted-by":"crossref","unstructured":"M. P\u00e9rol, B.J. Solomon, K. Goto et al., CNS protective effect of selpercatinib in first-line ret fusion-positive advanced non\u2013small cell lung cancer, J. Clin. Oncol. 42(21) (2024), doi: 10.1200\/JCO.24.00724.","DOI":"10.1200\/JCO.24.00724"},{"key":"10.1016\/j.lungcan.2026.109317_b0120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-based Chemotherapy","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:47:24Z","timestamp":1790700444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"alternative-id":["S0169500226000619"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109317","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109317"}}